Aim: Vascular congestion may lead to an increase of carbohydrate antigen 125 (CA-125). The role of CA-125 as a biomarker of congestion or for prognosis across the full ejection fraction (EF) spectrum of chronic heart failure (HF) remains unknown.
Methods And Results: Serum CA-125 was measured in 1111 study participants from the EMPEROR-Reduced and EMPEROR-Preserved trials. Congestive signs and symptoms were evaluated across CA-125 tertiles. Cox regression was used to study the association with outcomes. The primary outcome was a composite of first HF hospitalization or cardiovascular (CV) death. No significant association was present between baseline CA-125 levels and congestive signs or symptoms. In the overall population, higher CA-125 levels were not associated with an increased risk of primary outcome (tertile 3 vs. tertile 1: hazard ratio [HR] 1.34; 95% confidence interval [CI] 0.91-1.96; p-trend = 0.11). However, higher CA-125 levels were associated with an increased risk of primary outcome in patients with HF and reduced EF (HFrEF; tertile 3 vs. tertile 1: HR 2.25 [95% CI 1.30-3.89]), but not among patients with preserved EF (HFpEF; tertile 3 vs. tertile 1: HR 0.68 [95% CI 0.38-1.21]); interaction-p = 0.02). Patients in the upper CA-125 tertile also showed the steepest estimated glomerular filtration rate decline over time (p-trend = 0.03). The effect of empagliflozin to reduce the risk of CV death or HF hospitalization appeared to be attenuated in those with lower baseline CA-125 levels (interaction-p-trend = 0.09).
Conclusion: Across the range of EF in patients with chronic HF enrolled in the EMPEROR trials, the majority of whom did not have clinical evidence of congestion, CA-125 concentrations were not significantly associated with congestive signs or symptoms. CA-125 concentrations may predict HF hospitalization/CV death in patients with HFrEF, but not those with HFpEF.
Clinical Trial Registration: EMPEROR-Reduced (NCT03057977), EMPEROR-Preserved (NCT03057951).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ejhf.3166 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk factors for venous thromboembolism in patients undergoing neoadjuvant chemotherapy as treatment for ovarian cancer.
Eur J Obstet Gynecol Reprod Biol
December 2024
Department of Gynaecological Oncology, West Kent Cancer Centre, Maidstone and Tunbridge Wells NHS Trust, Hermitage Lane, Maidstone, Kent ME16 9QQ, United Kingdom.
Objective: During the treatment of ovarian cancer, the risk of venous thromboembolism (VTE) post operatively is well established, however, patients may be at even greater risk during neoadjuvant chemotherapy (NACT). This study aimed to determine the incidence and timing of VTE amongst patients undergoing NACT, whether there was an association with survival, and examine risk factors associated with the development of VTE.
Study Design: This was a retrospective cohort study of patients diagnosed with ovarian, fallopian tube and primary peritoneal cancer receiving neoadjuvant chemotherapy betweenApril 2011 and April 2022 at a gynaecological cancer centre in England.
Preoperative diagnosis of primary ovarian lymphoma: a case report and a decade of insights.
Front Oncol
December 2024
Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Through a comprehensive retrospective analysis of a 52-year-old woman with primary ovarian lymphoma (POL) and a review of similar cases over the past decade in the PubMed database, we gained several key insights into improving the understanding of POL among clinicians and radiologists for accurate diagnosis. POL is more prevalent among women in their 40s and usually presents with clinical manifestations of a solid mass (typically over 10 cm) and abdominal pain with B symptoms. Four imaging features show promise as indicators of potential diagnostic value in POL: the ovarian retention sign, touching ovaries, vascular floatation, and the sandwich sign.
View Article and Find Full Text PDFPseudo-Pseudo Meigs' Syndrome in a 40-Year-Old Woman Without a Prior Systemic Lupus Erythematosus Diagnosis.
Cureus
November 2024
Internal Medicine, Tbilisi State Medical University, Tbilisi, GEO.
Pseudo-pseudo Meigs' syndrome (PPMS), also known as Tjalma syndrome, is an exceptionally rare condition marked by pleural effusion, ascites, and elevated CA-125 levels, usually in the context of systemic lupus erythematosus (SLE) without any associated ovarian tumors. We report the case of a 40-year-old woman who presented with a four-month history of fatigue, nausea, weight loss, abdominal pain, and pleural effusion. Initial diagnostic workup revealed ascites, elevated CA-125 levels, and pleural effusions, with no evidence of malignancy.
View Article and Find Full Text PDFEffects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis.
ERJ Open Res
November 2024
National Heart and Lung Institute, Imperial College London, London, UK.
Background: Biomarkers that change in response to nintedanib in subjects with idiopathic pulmonary fibrosis (IPF) would be valuable. We investigated the effects of nintedanib on circulating biomarkers in subjects with IPF in the INMARK trial.
Methods: Subjects with IPF were randomised 1:2 to receive nintedanib 150 mg twice daily or placebo for 12 weeks, after which all patients received open-label nintedanib for 40 weeks.
Metabolic markers derived from 18F-FDG PET/CT in suspected recurrent ovarian carcinoma: predictive value for disease burden and prognosis.
Nucl Med Commun
December 2024
Department of Nuclear Medicine.
Objective: This study aims to assess the role of 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) in suspected recurrent ovarian carcinoma. Several clinical and PET parameters were assessed to evaluate disease burden and prognosis.
Methods: We did a single-center, retrospective study in patients with suspected recurrent ovarian carcinoma who underwent 18F-FDG PET/CT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!